AR032592A1 - Aminoalcoxicarbazoles y el uso de los mismos para la manufactura de un medicamento para el tratamiento de enfermedades del snc - Google Patents
Aminoalcoxicarbazoles y el uso de los mismos para la manufactura de un medicamento para el tratamiento de enfermedades del sncInfo
- Publication number
- AR032592A1 AR032592A1 ARP000104632A ARP000104632A AR032592A1 AR 032592 A1 AR032592 A1 AR 032592A1 AR P000104632 A ARP000104632 A AR P000104632A AR P000104632 A ARP000104632 A AR P000104632A AR 032592 A1 AR032592 A1 AR 032592A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- independently
- optionally substituted
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- -1 -OH Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Aminoalcoxicarbazoles, que proporcionan compuestos de la formula (1) o su sal farmacéuticamente aceptable, racemato, solvato, tautomero, isomero optico o su derivado profármaco; en donde R1 es H, halo, o C1-6 alquilo; cada R2 es independientemente H, halo, -OH, -CN, CF3, -O C1-6 alquilo, C1-6 alquilo, C3-6cicloalquilo, -NR5R6, -CONR5R6, -SO2NR5R6, -COOR7, -OCF3,o fenilo opcionalmente sustituido con halo, OH, O C1-4 alquilo, o C1-6 alquilo; cada R3 es independientemente H, C1-6 alquilo, o C3-6 cicloalquilo; R4 es arilo, o heteroarilo; R5 y R6 son independientemente H, C1-6 alquilo, o C3-6 cicloalquilo, R7 es H, C1-6 alquilo, o C1-3 alquil-fenilo en donde el fenilo puede estar sustituido con R3; R8 y R9 son independientemente H, C1-6 alquilo, opcionalmente sustituido con arilo, heteroarilo, o C3-6 cicloalquilo, C2-6 alqueno, C3-6 cicloalquilo, C2-6 alquilo sustituido con R10, -CHO, siempre que solamente uno de R8 y R9 sea CHO, y el otro sea H, arilo, heterociclo, en donde el heterociclo está unido a través de un átomo de carbono al nitrogeno al cual está unido, o R8 y R9 conjuntamente con el nitrogeno al cual están unidos forman un anillo heterocíclico en donde el anillo heterocíclico puede tener uno o dos heteroátomos seleccionados del grupo integrado por oxígeno, azufre y N(Y) y en donde los átomos de carbono del anillo heterocíclico están opcionalmente sustituidos con uno o dos R14; R10 es -OH, -O (C1-4 alquilo, ), opcionalmente el alquilo está sustituido con OH, -O(C1-4 alquil)-NR11R12, heterociclo, o -CO2R5; R11 y R12 son independientemente, H o C1-4 alquilo, arilo es fenilo o naftilo, opcionalmente sustituido con uno o más R13; heteroarilo es un radical que es un anillo aromático monocíclico de 5 o 6 miembros, con uno o dos heteroátomos, cada uno seleccionado del grupo integrado por oxígeno, azufre, y N(X), o un radical que es un anillo aromático bicíclico ortofusionado de 9 o 10 miembros, que tiene uno, dos o tres heteroátomos, cada uno seleccionado del grupo integrado por oxígeno, azufre, y N(X); en donde los átomos de carbono del heteroarilo pueden estar sustituidos con R13; heterociclo es un radical que es un anillo heterocíclico parcialmente saturado o no saturado, de 5, 6 o 7 miembros, con uno, dos o tres heteroátomos seleccionados del grupo integrado por oxígeno, azufre y N(Y), en donde los átomos de carbono del anillo heterocíclico pueden estar sustituidos con R14; X está ausente, o es H o C1-4 alquilo, Y es H, C1-6 alquilo, opcionalmente sustituido con arilo o heteroarilo, C3-6 cicloalquilo, o C2-6 alquilo sustituido con -OH, -O(C1-4 alquilo), -O(C1-4 alquil)-NR11R12, -CO2R5, o NHCHO, o -OH; R13 es halo, -OH, -CN, -CF3, -O C1-6 alquilo, C1-6 alquilo, C3-6 cicloalquilo, -NR5R6, -CONR5R6, -SO2NR5R6, -COOR7, -OCF3, o fenilo, opcionalmente sustituido con halo, OH, O C1-4 alquilo, o C1-6 alquilo; R14 es C1-6 alquilo, C3-6 cicloalquilo, C2-6 alquilo sustituido con -OH, -O (C1-4 alquilo), -O(C1-4 alquil)-NR11R12, o -CO2R5, -OH, u oxo (=O); m es 1, 2, 3 o 4; n es 1, 2, 3 o 4; en el C3-6 cicloalquilo de cada una de las definiciones anteriores, cada uno puede estar sustituido independientemente con -OH, C1-4 alquilo, u oxo (=O), y con las siguientes condiciones: (a) cuando R4 es 4-fluorofenilo, n es 1, m es 1, cada R3 es independientemente hidrogeno, R8 y R9 es independientemente -CH2CH3, entonces R2 no puede ser fluoro o cloro en la posicion C1-6 de la formula (1); (b) cuando n es 1, m es 1, R2, R3, R8 o R9 son hidrogeno, R4 es 4-tiazolilo, entonces dicho 4-tiazolilo no puede estar sustituido con 4-clorofenilo; (c) cuando n es 1, m es 1, R2, R3, R8 o R9 son hidrogeno, entonces R4 no es 4-piridilo; (d) cuando n es 1, m es 1, R2, R3, R8 o R9 son hidrogeno, entonces R4 no es 2-bromofenilo o 4-bromofenilo. Estos compuestos son ligandos de la 5-HT, y son utiles para tratar enfermedades en donde se desee modular la actividad de la 5-HT. Además se describe el uso de los mismos para la manufactura de un medicamento para tratar una enfermedad o condicion tal como ansiedad, depresion, esquizofrenia, una enfermedad relacionada con el estrés, un trastorno por pánico, una fobia, trastorno obsesivo-compulsivo, síndrome de estrés postraumático, depresion del sistema inmunologico, psicosis, parafrenia, manía, trastornos convulsivos, trastornos de la personalidad, cefalea por migrana, drogadiccion, alcoholismo, obesidad, trastornos de la alimentacion, o trastornos del sueno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15263899P | 1999-09-07 | 1999-09-07 | |
| US20377100P | 2000-05-12 | 2000-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032592A1 true AR032592A1 (es) | 2003-11-19 |
Family
ID=26849726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104632A AR032592A1 (es) | 1999-09-07 | 2000-09-05 | Aminoalcoxicarbazoles y el uso de los mismos para la manufactura de un medicamento para el tratamiento de enfermedades del snc |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6514968B1 (es) |
| EP (1) | EP1210329A2 (es) |
| JP (1) | JP2003508518A (es) |
| KR (1) | KR20020027622A (es) |
| CN (1) | CN1169789C (es) |
| AR (1) | AR032592A1 (es) |
| AU (1) | AU780190B2 (es) |
| BR (1) | BR0013767A (es) |
| CA (1) | CA2380763A1 (es) |
| CO (1) | CO5190697A1 (es) |
| MX (1) | MXPA02002496A (es) |
| MY (1) | MY125942A (es) |
| NZ (1) | NZ517661A (es) |
| PE (1) | PE20010522A1 (es) |
| WO (1) | WO2001017963A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SI1497266T1 (sl) | 2002-03-27 | 2008-10-31 | Glaxo Group Ltd | Derivati kinolina in njihova uporaba kot ligandi 5-ht6 |
| AU2003292508A1 (en) * | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
| AU2004261582C1 (en) | 2003-07-22 | 2010-01-07 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US7011871B2 (en) * | 2004-02-20 | 2006-03-14 | E. I. Du Pont De Nemours And Company | Charge transport compounds and electronic devices made with such compounds |
| CN101048402B (zh) * | 2004-10-29 | 2011-11-09 | 泽里新药工业株式会社 | 咔唑衍生物、其溶剂合物或其药学上允许的盐 |
| US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
| EP1856126A2 (en) * | 2005-02-17 | 2007-11-21 | Wyeth a Corporation of the State of Delaware | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
| ES2371106T3 (es) * | 2005-08-08 | 2011-12-27 | Astellas Pharma Inc. | Derivado de acilguanidina o sal del mismo. |
| WO2007077111A1 (en) * | 2005-12-30 | 2007-07-12 | F. Hoffmann-La Roche Ag | Compounds and methods for carbazole synthesis |
| ZA200806983B (en) * | 2006-02-20 | 2009-11-25 | Astellas Pharma Inc | Amide derivative or salt thereof |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| TW201033327A (en) * | 2008-12-12 | 2010-09-16 | Du Pont | Photoactive composition and electronic device made with the composition |
| US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| JP5766614B2 (ja) | 2009-01-09 | 2015-08-19 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 神経新生促進化合物 |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US8617720B2 (en) | 2009-12-21 | 2013-12-31 | E I Du Pont De Nemours And Company | Electroactive composition and electronic device made with the composition |
| EP2887803A4 (en) | 2012-08-24 | 2016-08-03 | Univ Texas | PRO-NEUROGENIC COMPOUNDS |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| US9902713B2 (en) | 2013-11-11 | 2018-02-27 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
| KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
| US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CN106045972B (zh) * | 2016-06-03 | 2018-11-16 | 中山大学 | 咔唑-利凡斯的明二联体及其药物组合物和应用 |
| CN107325143B (zh) * | 2017-08-07 | 2019-09-10 | 连云港恒运药业有限公司 | 氟维司群中间体合成方法 |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3759948A (en) | 1969-06-25 | 1973-09-18 | Merck & Co Inc | Non-steroid anti-inflammatory compounds |
| US3932424A (en) | 1970-06-15 | 1976-01-13 | Richardson-Merrell Inc. | Bis-basic ethers of carbazole |
| DE2815926A1 (de) | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US3896145A (en) | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5464746A (en) * | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| AU4685693A (en) | 1993-07-20 | 1995-02-20 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| DE4330175A1 (de) | 1993-08-31 | 1995-03-02 | Schering Ag | Alkoxy-substituierte beta-Carboline |
| DK139593D0 (da) | 1993-12-16 | 1993-12-16 | Lundbeck & Co As H | Compounds |
| FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
| US5668166A (en) | 1995-06-07 | 1997-09-16 | Georgia State University Research Foundation, Inc. | Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor |
| BR9713261A (pt) | 1996-10-30 | 2000-03-28 | Lilly Co Eli | Tricìclicos substituìdos |
-
2000
- 2000-08-24 MY MYPI20003905A patent/MY125942A/en unknown
- 2000-08-28 PE PE2000000882A patent/PE20010522A1/es not_active Application Discontinuation
- 2000-08-31 CA CA002380763A patent/CA2380763A1/en not_active Abandoned
- 2000-08-31 AU AU70532/00A patent/AU780190B2/en not_active Ceased
- 2000-08-31 KR KR1020027002955A patent/KR20020027622A/ko not_active Ceased
- 2000-08-31 WO PCT/US2000/020809 patent/WO2001017963A2/en not_active Ceased
- 2000-08-31 JP JP2001521710A patent/JP2003508518A/ja active Pending
- 2000-08-31 BR BR0013767-7A patent/BR0013767A/pt not_active IP Right Cessation
- 2000-08-31 CN CNB008123195A patent/CN1169789C/zh not_active Expired - Fee Related
- 2000-08-31 US US09/652,768 patent/US6514968B1/en not_active Expired - Fee Related
- 2000-08-31 MX MXPA02002496A patent/MXPA02002496A/es active IP Right Grant
- 2000-08-31 NZ NZ517661A patent/NZ517661A/en unknown
- 2000-08-31 EP EP00959165A patent/EP1210329A2/en not_active Withdrawn
- 2000-09-05 CO CO00066777A patent/CO5190697A1/es not_active Application Discontinuation
- 2000-09-05 AR ARP000104632A patent/AR032592A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1169789C (zh) | 2004-10-06 |
| MXPA02002496A (es) | 2002-07-30 |
| CA2380763A1 (en) | 2001-03-15 |
| CN1372547A (zh) | 2002-10-02 |
| WO2001017963A2 (en) | 2001-03-15 |
| AU7053200A (en) | 2001-04-10 |
| CO5190697A1 (es) | 2002-08-29 |
| JP2003508518A (ja) | 2003-03-04 |
| NZ517661A (en) | 2004-02-27 |
| AU780190B2 (en) | 2005-03-03 |
| WO2001017963A3 (en) | 2001-11-15 |
| BR0013767A (pt) | 2002-06-25 |
| PE20010522A1 (es) | 2001-04-28 |
| KR20020027622A (ko) | 2002-04-13 |
| US6514968B1 (en) | 2003-02-04 |
| EP1210329A2 (en) | 2002-06-05 |
| MY125942A (en) | 2006-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032592A1 (es) | Aminoalcoxicarbazoles y el uso de los mismos para la manufactura de un medicamento para el tratamiento de enfermedades del snc | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| AR040971A1 (es) | Compuestos pirimido que tienen actividad antiproliferativa | |
| JP2020519606A5 (es) | ||
| AR070852A1 (es) | Derivados de piridazina y su uso como agentes terapeuticos | |
| AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| BR9500996A (pt) | Derivado de difenila,agente terapêutico,processo para a preparação de um derivado de difenila,derivado de fenilpiperazina,composição farmacológica e métodos para fazer um medicamento e para tratar ou melhorar uma doença | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR035733A1 (es) | Compuestos heterociclicos terapeuticos, uso de dichos compuestos para la preparacion de medicamentos, compuestos relacionados y procedimientos para preparar estos compuestos relacionados | |
| RU2018130727A (ru) | Органические соединения | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| AR035493A1 (es) | Derivados de azepino (4,5b) indolina sustituidos, composicion farmaceutica y el uso de dichos derivados para preparar un medicamento | |
| AR037740A1 (es) | Compuestos azabiciclicos sustituidos de heteroarilos fusionados para el tratamiento de enfermedades, composiciones farmaceuticas, su uso en la preparacion de medicamentos | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR035612A1 (es) | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa | |
| AR044510A1 (es) | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina | |
| PE20240812A1 (es) | Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6 | |
| AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
| AR036600A1 (es) | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido [1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h) ona sustituidos | |
| AR036327A1 (es) | Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| PE20020063A1 (es) | Bis-arilsulfonas como ligandos del receptor de 5-ht |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |